3,4-Methylenedioxy-N-methoxyamphetamine
Appearance
Names | |
---|---|
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-methoxypropan-2-amine | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C11H15NO3 | |
Molar mass | 209.245 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
3,4-Methylenedioxy-N-methoxyamphetamine (MDMEO, MDMEOA, or MDMeOA) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxy analogue of MDA. MDMEO was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 180 mg. MDMEO may be found as white crystals. It produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEO.
Legality
[edit]United Kingdom
[edit]This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[1]
See also
[edit]References
[edit]- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.